Tenaya Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 140
- Market Cap
- $216.1M
- Introduction
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.
Tenaya's Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data
Tenaya Therapeutics' TN-201 gene therapy shows early efficacy and tolerability in treating MYBPC3-associated hypertrophic cardiomyopathy in the MyPeak-1 trial. No severe cardiac toxicities were reported, with manageable liver enzyme elevations. Efficacy signs include cardiac transduction and protein expression improvements. A higher dose cohort is now enrolling.
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease
The author discloses no stock positions in mentioned companies, no plans to initiate such positions within 72 hours, and no compensation for the article beyond Seeking Alpha. The article reflects the author's personal opinions, with no business relationships to mentioned companies. Seeking Alpha emphasizes past performance does not guarantee future results and does not provide investment advice.
Tenaya Therapeutics announces promising data from MyPEAK-1 phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated HCM
Tenaya Therapeutics announced encouraging early data from MyPEAK-1 trial of TN-201 gene therapy for MYBPC3-associated HCM, showing tolerability and transgene expression. Biomarkers and clinical markers showed stability or improvement, with longer-term data needed. Higher dose cohort results expected in 2025.
Tenya Therapeutics sees mixed success in HCM gene therapy trial
Tenaya Therapeutics shared 'encouraging' data from MyPEAK-1 trial of TN-201, treating MYBPC3-associated HCM, with biomarkers stable despite liver enzyme elevations. Stock dropped to $1.42 post-announcement.
Optimistic Outlook on Tenaya Therapeutics' TN-201 Gene Therapy for Hypertrophic Cardiomyopathy
H.C. Wainwright analyst Joseph Pantginis maintains a Buy rating on TNYA, optimistic about Tenaya Therapeutics’ TN-201 gene therapy for MYBPC3-associated HCM. Early Phase 1b MyPeak-1 study data show promising safety, tolerability, and potential efficacy, with ongoing studies expected to further validate TN-201's therapeutic potential.
Tenaya in selloff after early-stage data for gene therapy
Tenaya Therapeutics' stock plummeted after revealing initial Phase 1b/2 MyPEAK-1 trial results for gene therapy TN-201, aimed at treating cardiac conditions.
Tenaya Reports Early Data From First Cohort Of Patients In MyPEAK-1 Trial Of TN-201
Tenaya Therapeutics reported early TN-201 gene therapy data from MyPEAK-1 trial for MYBPC3-associated hypertrophic cardiomyopathy. Preliminary results from three patients showed TN-201 was well tolerated. Further data from Cohorts 1 and 2 expected by 2025. Tenaya's shares dropped 26% pre-market.
Tenaya Therapeutics Reports Promising Early Data from MyPEAK-1 Trial for TN-201 Gene Therapy
Tenaya Therapeutics reported early data from the MyPEAK-1 trial for TN-201 gene therapy, showing it's well-tolerated and effective in delivering MYBPC3 gene to heart cells, increasing MyBP-C protein levels. Initial results indicate stability or improvement in clinical measures, with further data expected in 2025.
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 Gene Therapy for MYBPC3-associated HCM
Tenaya Therapeutics to announce initial Cohort 1 data from MyPEAK-1 Phase 1b/2 trial of TN-201 gene therapy for MYBPC3-associated HCM on Dec 17, 2024, at 8:00 a.m. ET. A webcast and conference call will be hosted by Tenaya management. Archived replay available on their website.
First Patient Dosed in Cardiac Gene Therapy Trial
Roche plans to acquire Poseida Therapeutics for $1 billion to advance off-the-shelf CAR-T cell therapies. Tenaya Therapeutics dosed its first patient with TN-401 gene therapy for ARVC. The FDA granted RMAT designation to Intellia's nex-z CRISPR-based therapy for hereditary transthyretin amyloidosis.
© Copyright 2025. All Rights Reserved by MedPath